Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025.

Revenue
+22.7%
EPS
0.00%
Free cash flow
−159.7%
Total debt
+43.6%

Quarter to August 2026, against a year earlier

2.81 0.15 −5.07%
Market cap
$415.3M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
3/9
Altman Z
−1.96
Beneish M
−2.01
Dividend safety
n/a

Tilray Brands, Inc. (TLRY) P/E ratio

Alert me on P/E ratio

Tilray Brands, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 45.1× (March 2022) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2026 0.0× —
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2021 0.0× —
FY2020 0.0× —

Quarterly newest first

Period P/E ratio Change
Aug 2026 0.0× —
May 2026 0.0× —
Feb 2026 0.0× —
Nov 2025 0.0× —
40 more quarters

Against its own ten years

Low 0.0× High 45.1×
Ten-year median 0.0×
Current reading's percentile 97

P/E ratio against peers

Company P/E ratio
TKNO Alpha Teknova, Inc. compare n/m
AQST Aquestive Therapeutics, Inc. compare n/m
ACB Aurora Cannabis Inc. compare n/m
EVO Evotec AG compare n/m
TLRY Tilray Brands, Inc. n/m
EOLS Evolus, Inc. compare n/m
CGC Canopy Growth Corporation compare n/m
IRWD Ironwood Pharmaceuticals, Inc. compare 4.3×
KMDA Kamada Ltd. compare 18.1×
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on TLRY